Mid to Long-Term Echocardiographic Follow-up of Patients Undergoing Transcatheter Tricuspid Valve-in-Valve Replacement for Degenerated Bioprosthetic Valves: First Single-Center Report from Iran.
Mohammad Sahebjam, Alimohammad Haji Zeinali, Kyomars Abbasi, Solmaz Borjian
{"title":"Mid to Long-Term Echocardiographic Follow-up of Patients Undergoing Transcatheter Tricuspid Valve-in-Valve Replacement for Degenerated Bioprosthetic Valves: First Single-Center Report from Iran.","authors":"Mohammad Sahebjam, Alimohammad Haji Zeinali, Kyomars Abbasi, Solmaz Borjian","doi":"10.18502/jthc.v17i3.10843","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Transcatheter tricuspid valve-in-valve (TTViV) replacement has become an alternative treatment in high-risk patients with bioprosthetic valve degeneration. This is the first report on the mid to long-term echocardiographic findings of patients who underwent TTViV replacement in a cardiac referral center in Iran.</p><p><strong>Methods: </strong>Data of 12 patients, consisting of 11 women and 1 man, who underwent TTViV replacement between 2015 and 2021 were reviewed retrospectively. The patients underwent echocardiography before the procedure and at a mean follow-up time of 3.17±1.75 years.</p><p><strong>Results: </strong>All the patients had New York Heart Association (NYHA) function class III/IV before TTViV. Six patients had tricuspid regurgitation, 1 had tricuspid stenosis, and 5 had both. All the patients had successful TTViV. The mean time from the initial valve surgery to TTViV was 6.25±2.45 years. At follow-up, 2 patients had died: 1 due to COVID-19 pneumonia and 1 without a known cause. The remaining 10 patients experienced improvements in the NYHA functional class. Echocardiographic measures showed significant improvements. Transvalvular mean gradient pressure decreased from 7.08±1.98 mm Hg to 5.29±1.63 mm Hg (P=0.028), tricuspid valve pressure half time decreased from 245.00±49.46 ms to 158.64±57.41 ms (P=0.011), tricuspid regurgitation gradient decreased from 39.91±7.31 mm Hg to 26.72±8.99 mm Hg, and left ventricular ejection fraction increased from 47.71±4.70% to 49.79±4.58% (P=0.046). There was no significant paravalvular or transvalvular leakage at follow-up.</p><p><strong>Conclusion: </strong>This is a single-center report on the mid and long-term echocardiographic follow-up of patients after TTViV replacement. Our study showed that TTViV was a safe and efficient method in treating high-risk patients with degenerated bioprosthetic tricuspid valves and had favorable echocardiographic and clinical results.</p>","PeriodicalId":39149,"journal":{"name":"Journal of Tehran University Heart Center","volume":"17 3","pages":"112-118"},"PeriodicalIF":0.0000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d7/9f/JTHC-17-112.PMC10222937.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Tehran University Heart Center","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/jthc.v17i3.10843","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Transcatheter tricuspid valve-in-valve (TTViV) replacement has become an alternative treatment in high-risk patients with bioprosthetic valve degeneration. This is the first report on the mid to long-term echocardiographic findings of patients who underwent TTViV replacement in a cardiac referral center in Iran.
Methods: Data of 12 patients, consisting of 11 women and 1 man, who underwent TTViV replacement between 2015 and 2021 were reviewed retrospectively. The patients underwent echocardiography before the procedure and at a mean follow-up time of 3.17±1.75 years.
Results: All the patients had New York Heart Association (NYHA) function class III/IV before TTViV. Six patients had tricuspid regurgitation, 1 had tricuspid stenosis, and 5 had both. All the patients had successful TTViV. The mean time from the initial valve surgery to TTViV was 6.25±2.45 years. At follow-up, 2 patients had died: 1 due to COVID-19 pneumonia and 1 without a known cause. The remaining 10 patients experienced improvements in the NYHA functional class. Echocardiographic measures showed significant improvements. Transvalvular mean gradient pressure decreased from 7.08±1.98 mm Hg to 5.29±1.63 mm Hg (P=0.028), tricuspid valve pressure half time decreased from 245.00±49.46 ms to 158.64±57.41 ms (P=0.011), tricuspid regurgitation gradient decreased from 39.91±7.31 mm Hg to 26.72±8.99 mm Hg, and left ventricular ejection fraction increased from 47.71±4.70% to 49.79±4.58% (P=0.046). There was no significant paravalvular or transvalvular leakage at follow-up.
Conclusion: This is a single-center report on the mid and long-term echocardiographic follow-up of patients after TTViV replacement. Our study showed that TTViV was a safe and efficient method in treating high-risk patients with degenerated bioprosthetic tricuspid valves and had favorable echocardiographic and clinical results.
背景:经导管三尖瓣瓣内置换术(TTViV)已成为高危生物瓣膜退行性变患者的替代治疗方法。这是第一份关于在伊朗心脏转诊中心接受TTViV置换的患者中长期超声心动图结果的报告。方法:回顾性分析2015 - 2021年间行TTViV置换术的12例患者的资料,其中11例为女性,1例为男性。患者术前行超声心动图检查,平均随访时间3.17±1.75年。结果:所有患者在TTViV前均为纽约心脏协会(NYHA)功能III/IV级。6例有三尖瓣反流,1例有三尖瓣狭窄,5例两者皆有。所有患者均成功进行了TTViV治疗。从首次瓣膜手术到TTViV的平均时间为6.25±2.45年。随访时,2例患者死亡:1例死于COVID-19肺炎,1例死因不明。其余10例患者的NYHA功能分级有所改善。超声心动图显示明显改善。经瓣平均梯度压由7.08±1.98 mm Hg降至5.29±1.63 mm Hg (P=0.028),三尖瓣压力半时间由245.00±49.46 ms降至158.64±57.41 ms (P=0.011),三尖瓣反流梯度由39.91±7.31 mm Hg降至26.72±8.99 mm Hg,左室射血分数由47.71±4.70%上升至49.79±4.58% (P=0.046)。随访时无明显的瓣旁或跨瓣渗漏。结论:这是一篇关于TTViV置换术后患者中长期超声心动图随访的单中心报告。我们的研究表明,TTViV是一种安全有效的治疗高危生物假体三尖瓣退行性变的方法,超声心动图和临床结果良好。